Q2 2022 13F Holders as of 6/30/2022
-
Type / Class
-
Equity / Common Stock, par value $0.001 per share
-
Shares outstanding
-
40.2M
-
Number of holders
-
31
-
Total 13F shares, excl. options
-
5.93M
-
Shares change
-
-567K
-
Total reported value, excl. options
-
$18.4M
-
Value change
-
-$2.06M
-
Number of buys
-
9
-
Number of sells
-
-17
-
Price
-
$2.93
Significant Holders of Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share (TARA) as of Q2 2022
35 filings reported holding TARA - Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share as of Q2 2022.
Protara Therapeutics, Inc. - Common Stock, par value $0.001 per share (TARA) has 31 institutional shareholders that have filed 13F forms with the Securities Exchange Commission (SEC).
These institutions hold a total of 5.93M shares
of 40.2M outstanding shares and own 14.73% of the company stock.
Largest 10 shareholders include Opaleye Management Inc. (2.68M shares), ORBIMED ADVISORS LLC (831K shares), VANGUARD GROUP INC (427K shares), PERCEPTIVE ADVISORS LLC (290K shares), Ikarian Capital, LLC (258K shares), CITADEL ADVISORS LLC (243K shares), BOXER CAPITAL, LLC (209K shares), BAKER BROS. ADVISORS LP (200K shares), DLD Asset Management, LP (157K shares), and GEODE CAPITAL MANAGEMENT, LLC (83.6K shares).
This table shows the top 31 institutional shareholders of the company equity. This data is sourced directly from the SEC via 13F filings.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price $ |
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.